US 12,133,678 B2
Apparatus and methods to modulate bladder function
Dan Sachs, Maple Grove, MN (US); and Edwin J. Hlavka, Minneapolis, MN (US)
Assigned to Hologic, Inc., Marlborough, MA (US)
Filed by HOLOGIC, INC., Marlborough, MA (US)
Filed on Jul. 11, 2023, as Appl. No. 18/350,189.
Application 18/350,189 is a continuation of application No. 17/561,925, filed on Dec. 25, 2021, granted, now 11,723,719.
Application 17/561,925 is a continuation of application No. 16/192,109, filed on Nov. 15, 2018, granted, now 11,229,482, issued on Jan. 25, 2022.
Application 16/192,109 is a continuation of application No. 14/328,636, filed on Jul. 10, 2014, granted, now 10,166,068, issued on Jan. 1, 2019.
Application 14/328,636 is a continuation of application No. 14/030,869, filed on Sep. 18, 2013, granted, now 9,095,351, issued on Aug. 4, 2015.
Application 14/030,869 is a continuation of application No. PCT/US2012/048419, filed on Jul. 26, 2012.
Claims priority of provisional application 61/565,460, filed on Nov. 30, 2011.
Claims priority of provisional application 61/511,776, filed on Jul. 26, 2011.
Prior Publication US 2023/0355304 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 18/14 (2006.01); A61B 18/04 (2006.01); A61B 18/18 (2006.01); A61B 18/24 (2006.01); A61F 7/12 (2006.01); A61B 18/00 (2006.01)
CPC A61B 18/1492 (2013.01) [A61B 18/04 (2013.01); A61B 18/1477 (2013.01); A61B 18/1485 (2013.01); A61B 18/18 (2013.01); A61B 18/1815 (2013.01); A61B 18/24 (2013.01); A61F 7/12 (2013.01); A61B 2018/00023 (2013.01); A61B 2018/00083 (2013.01); A61B 2018/0022 (2013.01); A61B 2018/00267 (2013.01); A61B 2018/00517 (2013.01); A61B 2018/00523 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/143 (2013.01); A61B 2018/183 (2013.01); A61B 2018/1861 (2013.01)] 20 Claims
OG exemplary drawing
 
18. A method to modulate bladder function of a patient, comprising:
introducing an energy delivery device into a space between a posterior bladder wall and an anterior vaginal wall of the patient; and
delivering energy from the energy delivery device into non-superficial target tissue located between the posterior bladder wall and the anterior vaginal wall, thereby interrupting afferent receptors in the non-superficial target tissue, while maintaining cellular viability of a mucosal surface of the posterior bladder wall and of the anterior vaginal wall.